Federal grants to Molecular Targeting Technologies, Inc.
Molecular Targeting Technologies, Inc. in West Chester, Pennsylvania received $3.2 million in federal grants from fiscal 2021 to 2025, across 3 awards. Its largest program was Cancer Treatment Research, with $2.0 million. In fiscal 2025 more was taken back from its awards than added, a net -$86,172.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$3.2 million
- Awards3
- Awarded in FY 2025-$86,172
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $514,387 |
| FY 2022 | 2 | $1.5 million |
| FY 2023 | 2 | $1.3 million |
| FY 2024 | 0 | $0 |
| FY 2025 | 0 | -$86,172 |
Programs that fund Molecular Targeting Technologies, Inc.
| Program | Awards | Amount |
|---|---|---|
| Cancer Treatment Research | 1 | $2.0 million |
| Cancer Detection and Diagnosis Research | 1 | $929,178 |
| Cardiovascular Diseases Research | 1 | $299,890 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 3 | $3.2 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Instantaneous tumor spray for real-time surgical guidance - early stage ovarian cancer is typically asymptomatic. Undiagnosed until the disease has reached an advanced stage, the disease presents extensive intra-abdominal peritoneal metastases. Standard of care treatment includes either a surgical c | Cancer Treatment Research | August 10, 2022 | $2.0 million |
| Early prediction of tumor response to treatment: clinical translation of [99MTC]-duramycin | Cancer Detection and Diagnosis Research | December 30, 2020 | $929,178 |
| Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk - we propose to develop a novel antithrombotic agent with improved efficacy and safety over standard of care via the following properties: 1) specific targeting to procoagulant surfaces, 2) high coagulan | Cardiovascular Diseases Research | January 31, 2023 | $299,890 |
Questions people ask
How much federal grant money does Molecular Targeting Technologies, Inc. get?
$3.2 million in 3 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Molecular Targeting Technologies, Inc. the most?
The Department of Health and Human Services, with $3.2 million in 3 awards.
What is Molecular Targeting Technologies, Inc.'s largest federal grant?
$2.0 million under Cancer Treatment Research, with its first action in the period on August 10, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Molecular Targeting Technologies, Inc.?
Its largest are Cancer Treatment Research, Cancer Detection and Diagnosis Research and Cardiovascular Diseases Research.
Other grant recipients in West Chester
- West Chester University of Pennsylvania
- The Devereux Foundation
- County of Chester
- Housing Authority of the County of Chester
- The Devereux Foundation
- Ymic Foundation, Inc.
- Tiptek, LLC
- Onocor LLC
Largest federal grant recipients in Pennsylvania · Federal grants in Pennsylvania